Eli Lilly & Co. and Novo Nordisk A/S are leveraging a fresh weapon in their crackdown against copycat versions of their blockbuster weight loss drugs.

The two pharmaceutical giants over the last year have filed 10 cases against compounders and telehealth companies with BBB National Programs’ National Advertising Division, a self-regulatory body providing dispute resolution over advertising claims. The non-government group has been around since 1971, settling disagreements over products from bathroom cleaners to infant formula — but the GLP-1 drugmakers turned to it relatively recently.

It’s another avenue in the aggressive fight to rein in unapproved versions of their …